Olanzapine: A potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics.
Journal
Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
22
11
2018
accepted:
05
03
2019
entrez:
20
4
2019
pubmed:
20
4
2019
medline:
6
5
2020
Statut:
epublish
Résumé
Designer receptors exclusively activated by designer drugs (DREADDs) derived from muscarinic receptors not only are a powerful tool to test causality in basic neuroscience but also are potentially amenable to clinical translation. A major obstacle, however, is that the widely used agonist clozapine
Identifiants
pubmed: 31001591
doi: 10.1126/sciadv.aaw1567
pii: aaw1567
pmc: PMC6469940
doi:
Substances chimiques
Designer Drugs
0
Receptor, Muscarinic M4
0
Serotonin Uptake Inhibitors
0
Olanzapine
N7U69T4SZR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
eaaw1567Subventions
Organisme : Medical Research Council
ID : G0802158
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0900613
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0501424
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/L01095X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0400136
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0600368
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0400627
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : G116/147
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0601440
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 209807/Z/17/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 212285/Z/18/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : G9805989
Pays : United Kingdom
Références
Nat Med. 2003 Aug;9(8):1076-80
pubmed: 12858168
Neuropsychopharmacology. 2008 Sep;33(10):2303-12
pubmed: 18059438
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 2;81:122-130
pubmed: 29097257
ACS Chem Neurosci. 2015 Mar 18;6(3):476-84
pubmed: 25587888
Science. 2017 Aug 4;357(6350):503-507
pubmed: 28774929
Sci Rep. 2018 Mar 1;8(1):3840
pubmed: 29497149
Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5163-8
pubmed: 17360345
J Chem Inf Model. 2010 Apr 26;50(4):572-84
pubmed: 20235588
Neuron. 2016 Feb 17;89(4):683-94
pubmed: 26889809
Biol Psychiatry. 1996 Mar 1;39(5):367-70
pubmed: 8704069
N Engl J Med. 2011 Sep 8;365(10):919-26
pubmed: 21899452
Brain. 2008 Jun;131(Pt 6):1506-15
pubmed: 18477594
Nat Commun. 2014 May 27;5:3847
pubmed: 24866701
FEBS Lett. 2015 Jun 22;589(14):1620-34
pubmed: 25979170
Am J Physiol Cell Physiol. 2005 Sep;289(3):C543-56
pubmed: 15857907
Mol Ther. 2009 Oct;17(10):1692-702
pubmed: 19638961
J Med Chem. 2007 Jan 11;50(1):74-82
pubmed: 17201411
J Comput Aided Mol Des. 2013 Mar;27(3):221-34
pubmed: 23579614
Sci Transl Med. 2012 Nov 21;4(161):161ra152
pubmed: 23147003
J Biol Chem. 2000 Jan 14;275(2):921-9
pubmed: 10625628
Front Neurol. 2017 Jul 06;8:301
pubmed: 28729850
Epilepsia. 2002;43(s2):19-24
pubmed: 11903478
Neuropsychopharmacology. 1996 Feb;14(2):87-96
pubmed: 8822531
PLoS One. 2013;8(1):e53459
pubmed: 23326434
Lancet Neurol. 2014 Nov;13(11):1114-1126
pubmed: 25316018
J Neurosci. 2004 Mar 24;24(12):3051-9
pubmed: 15044544
Nucleic Acids Res. 2015 Jul 1;43(W1):W612-20
pubmed: 25883136
Nature. 2013 Dec 5;504(7478):101-6
pubmed: 24256733
ACS Pharmacol Transl Sci. 2018 Sep 14;1(1):61-72
pubmed: 30868140
Nat Rev Drug Discov. 2004 Apr;3(4):353-9
pubmed: 15060530
Nat Med. 2018 Sep;24(9):1324-1329
pubmed: 29988123
Exp Neurol. 2016 Sep;283(Pt A):404-12
pubmed: 27404844
Brain. 2010 Sep;133(9):2778-88
pubmed: 20688813
Behav Brain Res. 2011 Mar 1;217(2):337-46
pubmed: 21056063
Nat Rev Drug Discov. 2015 Jul;14(7):475-86
pubmed: 26091267
ACS Chem Neurosci. 2013 Jul 17;4(7):1018-25
pubmed: 24047509
Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082
pubmed: 29126136